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Abstract
Apoptosis is a biological process relevant to human disease
states that is strongly regulated through protein–protein
complex formation. These complexes represent interesting
points of chemical intervention for the development of
molecules that could modulate cellular apoptosis. The
apoptosome is a holoenzyme multiprotein complex formed
by cytochrome c-activated Apaf-1 (apoptotic protease-
activating factor), dATP and procaspase-9 that link mitochon-
dria disfunction with activation of the effector caspases and
in turn is of interest for the development of apoptotic
modulators. In the present study we describe the identifica-
tion of compounds that inhibit the apoptosome-mediated
activation of procaspase-9 from the screening of a diversity-
oriented chemical library. The active compounds rescued
from the library were chemically optimised to obtain
molecules that bind to both recombinant and human
endogenous Apaf-1 in a cytochrome c-noncompetitive
mechanism that inhibits the recruitment of procaspase-9 by
the apoptosome. These newly identified Apaf-1 ligands
decrease the apoptotic phenotype in mitochondrial-mediated
models of cellular apoptosis.
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Introduction
Protein–protein interactions play a critical role in almost
all cellular and biological processes. Consequently, the
interactions between proteins represent points of chemical
intervention for therapeutic gain in the biological processes
associated with disease. Apoptosis is an interesting biological
process because of its importance in a wide variety of
biological systems, including normal cell turnover, the immune
system and embryonic development and its association
with different diseases. Inappropriate apoptosis is involved
in many human pathologies, including neurodegenerative
diseases such as Alzheimer’s and Huntington’s, ischaemia,
autoimmune disorders and several forms of cancer.1 Diverse
apoptotic stimuli, including activation of cell surface
death receptors, anticancer agents, irradiation, lack of
survival factors, and ischaemia (reviewed in Strasser et al2)
induce signalling cascades that all activate a family of cysteine
aspartyl proteases called caspases. It is these proteases
that execute the apoptotic process. Effector caspases (e.g.
caspases-3 and -7) are responsible for the disassembly
of cellular components while initiator caspases (e.g. cas-
pases-8, -9 and -10) are responsible for activation of the
effector caspases. While different apoptotic stimuli activate
different initiators, these initiators activate a common set of
effector caspases. Because of the critical consequences
of apoptosis malfunctioning, the activation of caspases is
scrupulously controlled. Some apoptotic signals activate
the mitochondria-mediated or intrinsic pathway that utilises
caspase-9 as its initiator. Caspase-9 activation is triggered
by the release to the cytosol of proapoptotic proteins from
the mitochondrial inter-membrane space, in particular cyto-
chrome c and Smac/Diablo.3,4 The formation of the macro-
molecular complex named apoptosome is a key event
in this pathway. The apoptosome is a holoenzyme multi-
protein complex formed by cytochrome c-activated Apaf-1
(apoptotic protease-activating factor), dATP and pro-
caspase-9.5–8 In this macromolecular complex, apoptosome-
associated caspase-9 is activated and then, in turn,
activate effector caspases. To identify molecules that could
ameliorate disease-associated apoptosis, drug discovery
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efforts have initially targeted caspase activity9,10 rather than
activation. Nevertheless, protein–protein interactions up-
stream of caspase activation can be also relevant points
of intervention for the development of modulators of apoptosis
pathways. In particular, recent data propose the formation
of the apoptosome as an interesting target for the develop-
ment of apoptotic modulators.11–14 In the absence of
detailed structural information, the conventional methods
used for the identification of modulators of the apopto-
some have been based in indirect measurements of
the cytochrome c- and dATP-induced activation of caspase-
3-like activity on defined cytosolic extracts.15,16 Using
this methodology Lademann et al.15 have identified
inhibitors of the apoptosome through the screening
of small molecules using cytosolic extracts of selected
cells while Nguyen et al.16 reported the identification of
activators.
We are currently engaged in a discovery program employ-
ing an in vitro reconstituted active apoptosome assembled
from its recombinant constituent proteins. Here we describe
the identification of compounds that inhibit the apoptosome-
mediated activation of procaspase-9 from the screening of
a diversity-oriented chemical library of N-alkylglycines. The
active compounds rescued from the library were chemically
optimised to obtain molecules that bind to both recombinant
and human endogenous Apaf-1 and decrease the apoptotic
phenotype in mitochondrial-mediated models of cellular
apoptosis.
Results
Screening of a positional scanning library of
peptoids as a source for apoptosome inhibitors
Oligomers of N-alkylglycines, also known as peptoids,
constitute a family of non-natural molecules attractive for the
drug discovery process due to their broad variety of biological
activities and to the proteolytic stability that they exhibit.17,18
We have early designed a positional scanning diversity-
oriented combinatorial library of trimers of N-alkylglycines19
that allowed the identification of lead compounds in different
biological assays.20–22 We have now modified the diversity of
the library to generate an optimised version of the original
library in terms of composition and concentration of the
different components.23 The library consists in 52 controlled
mixtures and a total of 5120 compounds. The mixtures were
screened for their ability to prevent the apoptosome-depen-
dent activation of procaspase-9. The apoptosome was
assembled in vitro by incubating rApaf-1, cytochrome c, dATP
and [35S]Met procaspase-9 (see Materials and Methods
section and Supplementary information). Samples were
subjected to SDS-PAGE and caspase-9 processing subse-
quently visualised by phospho-imaging. Defined mixtures
from the library inhibited the apoptosome-dependent activa-
tion and allowed the deconvolution process and identifi-
cation of four discrete compounds (peptoids 1–4, Figure 1a)
that inhibited the apoptosome-dependent activation of
Figure 1 Peptoids rescued from the library inhibit apoptosome dependent procaspase-9 processing in an in vitro assay. (a) Chemical structures of peptoids 1 to 4
rescued from the screening of the library of N-alkylglycines. (b) Chemical structures of peptoids 1a and 1b. (c) Peptoid 1a (upper panel) and peptoid 1b (lower panel)
were evaluated in a concentration-dependent manner for their capacity to inhibit apoptosome-dependent activation of procaspase-9
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procaspase-9 to different extent in a concentration-dependent
manner. A peptoid from our stock collection was used as
negative control. The most potent inhibitor was peptoid 1.
However, probably due to the overall intrinsic hydrophobicity
of all four compounds, problems of reproducibility were
encountered from batch-to-batch solubilised peptoids. Then
we decided to generate more soluble analogues of peptoid 1.
Previous experience in the design of bioactive peptides24,25
suggested that the presence of positively charged side chains
at both N- and C-terminus ends of peptides increased the
overall peptide solubility without modifying their conforma-
tional or biological properties. Furthermore, in our laboratory,
we have used an N-substituted alkylglycine hexamer com-
posed by residues containing a simple benzene ring or a
tertiary amino moiety attached to a bioactive hexapeptide
sequence to increase both aqueous solubility and cell-
membrane permeability (unpublished results). With these
precedents, peptoids 1a and 1b containing two additional
N-alkylamine residues at the N- or C-terminus ends,
respectively, were synthesised (Figure 1b) and their in vitro
activity tested. These two peptoids inhibited the apoptosome-
mediated procaspase-9 activation with an excellent batch-to-
batch reproducibility and an IC50 close to 10 mM (Figure 1c).
Preliminary structure–activity relationship analysis on the
peptoid 1 family suggested that the dichlorophenylethylamino
moiety was important for activity. Peptoid 1d, derived from
peptoid 1b with a deletion at the N-terminus of an
N-dichlorophenylethylglycine, had a reduced inhibitory activity
when compare to peptoid 1b (results not shown) in the in vitro
apoptosome activity assay.
Peptoid 1a inhibited caspase-3 processing (Figure 2a)
when the apoptosome activity was followed in the presence of
rApaf-1, cytochrome c, dATP, and both in vitro translated
[35S]Met procaspase-9 and -3 (see Materials and Methods
section). Furthermore, we tested apoptosome-dependent
caspase-3 activation by adding rApaf-1 to an Apaf-1 free cell
extract14 and measuring Ac-DEVD-afc hydrolysis (DEVDase
activity; Figure 2b). This confirmed a dose-dependent
inhibitory activity of the peptoids in this assay that correlated
with their ability to inhibit apoptosome formation (Figure 1c). It
is worth mentioning that a recombinant caspase 3 activity in
vitro assay (Calbiochem) showed that the inhibitory properties
of peptoid 1a were not due to a direct inhibition of caspase 3
(data not shown).
Peptoid 1a directly binds to rApaf-1 and induces a
nonactive apoptosome complex
The apoptosome is assembled when seven Apaf-1:cyto-
chrome c heterodimers oligomerise to form a ‘wheel’ structure
that has the ability to recruit procaspase-9.6,26–28 To initially
characterise the binding site of the peptoids to the apopto-
some, we synthesised a fluorescent analogue of peptoid 1a
(peptoid f1a). Peptoid f1a bound to rApaf-1, but not to
cytochrome c and other control proteins (Figure 3A), with
dissociation constant (Kd) 57712 nM as determined in a
fluorescence polarisation assay. Nevertheless, the binding
constant value contrasted with the concentration of peptoid 1a
that was needed to inhibit 50% of caspase activity in our
assays (IC50B10 mM, Figure 1c). A putative explanation to
reconcile these data is that the reticulocyte lysate used to in
vitro translate procaspase-9 contained components that
diminished the effective concentration of peptoid 1a.
Next, we evaluated whether or not peptoid 1a inhibits
cytochrome c binding to rApaf-1. In the fluorescence
polarisation assay, the dissociation constant for the interac-
tion rApaf-1/peptoid f1a was not influenced by the presence
of up to five-fold molar excess of cytochrome c (not shown).
Furthermore, we also performed the in vitro apoptosome
reconstitution assay in the presence of increasing concentra-
tions of cytochrome c. Regardless of the concentration
of cytochrome c used, peptoid 1a exerted its inhibitory
activity on apoptosome-dependent procaspase-9 cleavage
(Figure 3B). These results suggest that peptoid 1a directly
binds to rApaf-1 in a binding site different from that of
the cytochrome c recruitment site and induces a conforma-
tional change in Apaf-1 that precludes procaspase-9 proces-
sing. In principle, the peptoid may have prevented any
of the steps leading to caspase-9 activation including Apaf-1
oligomerisation and caspase recruitment.26 To test which
step of caspase activation was blocked, rApaf-1 was
incubated in the presence and absence of peptoid 1a,
cytochrome c and dATP and the ability to activate caspases
from cell lysates was evaluated before and after chromato-
graphy on Superose-6 H-R analytical gel filtration
column. Before gel filtration (Figure 3C; sample a is a
control only containing FT extract), the sample containing
rApaf-1, cytochrome c and dATP (sample b) was able to
activate caspases and this was inhibited by peptoid 1a
Figure 2 Peptoid 1a inhibits apoptosome mediated caspase-3 activation. (a)
Left panel. In vitro translated [35S]Met procaspase-9 and procaspase-3 were
incubated in the presence of rApaf-1, cytochrome c and in the presence or
absence of peptoid 1a (20 mM). Right panel. In vitro translated procaspase-9 and
[35S]Met procaspase-3 were incubated in the presence of rApaf-1, cytochrome c
and in the presence or absence of peptoid 1a. (b) DEVDase activity on FT
extracts was measured in the presence or absence of increasing concentrations
of both peptoid 1a (&) and peptoid 1b (E). rApaf-1 was incubated with peptoids
at 301C for 30 min and combined with a 5 ml aliquot of FT extract. DEVDase
activity was measured and referred to a positive control (100% activity)
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(sample c). Aliquots from samples a, b and c were subjected
to gel filtration chromatography and the DEVDase activity of
collected fractions was evaluated (Figure 3D). The elution
profile of sample b showed a major peak, with DEVDase
activity, centred on fraction 22 that corresponds to a size of
B700 kDa. This is consistent with the reported size of the
active apopotosome.29,30 The DEVDase activity of fraction
22 was inhibited in the presence of peptoid 1a (inset in
Figure 3D). However, the elution profile of sample c showed a
very low DEVDase activity around fraction 18 and we could
not detect the presence of Apaf-1 in this fraction by
immunoblot (not shown). These data suggest that in the
presence of cytochrome c and dATP, monomeric rApaf-1
could be induced to form aB700 kDa active complex. Peptoid
1a could bind to monomeric or complexed rApaf-1 and induce
a conformational change in rApaf-1 rendering a poorly active
conformation. To determine whether or not peptoid 1a-
inhibited apoptosome is capable of procaspase-9 recruitment,
we performed a rApaf-1-mediated pull-down experiment
(Figure 3E). Noncleavable [35S]Met procaspase-9 was
coprecipitated with rApaf-1 in the presence of cytochrome c
and dATP (lane 3, Figure 3E). However, the presence of
peptoid 1a precludes recruitment of procaspase-9 by the
apoptosome (lane 4, Figure 3E).
Figure 3 Peptoid 1a binds to and induces a conformational change on rApaf-1. (A) A 60 nM solution of peptoid f1a in buffer A was titrated with increasing
concentrations of rApaf-1 (’), cytochrome c (E), RNAase A (J), synthetic tetramerisation domain of p53 (K), aldolase (&), catalase (B) and fluorescence
polarization was measured at 301C. The data (mean S.D.; n¼ 3) were recorded in millipolarization units (mP) and adjusted to a two-state binding model. (B)
Apoptosome-dependent activation of procaspase-9 was followed by incubating in vitro transcribed-translated [35S]Met procaspase-9 and rApaf-1 in the presence or
absence of peptoid 1a (20 mM) at different concentrations of cytochrome c. (C) Three different sample preparations of rApaf-1 were used in conjunction with FT aliquots
from cell lysates (see Material and Methods section) to determine caspase processing activity by measuring DEVDase activity. Sample a, contains rApaf-1 but no
cytochrome c; sample b and sample c contain rApaf-1, cytochrome c and dATP in the absence (b) or in the presence (c) of peptoid 1a (50 mM) that was incubated with
rApaf-1 for 30 min at 301C prior addition to the FT aliquot. (D) Samples a, b and c were applied to Superose 6 H-R column and elution fractions were used in conjunction
with FT aliquots to determine DEVDase activity (diamonds, filled squares and white triangles denote activity for fractions from samples a, b and c, respectively). Inset.
The DEVDase activity of aliquots of fraction 22 was also determined in the absence (F22) or in the presence of peptoid 1a (F22þ peptoid 1a). (E) rApaf-1-mediated pull-
down of procaspase-9. Aliquots from samples a, b and c were combined with a 5 ml aliquot of an in vitro translation reaction of noncleavable [35S]Met procaspase-9
(procaspase-9 mutant D315/330A) and mixed with Ni2þ -NTA-agarose beads. After centrifugation, the material eluted from the beads was subjected to SDS-PAGE.
Lane 1, control no rApaf-1; lane 2–4, recovery from samples a, b and c, respectively
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Peptoid 1a inhibits human endogenous Apaf-1 and
decrease apoptotic phenotype in cellular models
of drug induced apoptosis
Next, we tested whether peptoid 1a is able to inhibit cellular
Apaf-1 as it inhibits rApaf-1. We used a cell-free system
obtained from 293 cells.31 This extract was fractioned on a
Q-sepharose column that, as mentioned before, results in a
fraction (named F1) enriched in endogenous Apaf-1 and a
flow-through fraction (named FT) that contains cytochrome c
and caspases, thus separating the components needed for
caspase-9/-3 activation. These two fractions could effectively
reconstitute caspase activation. However, when the F1
fraction was preincubated with peptoid 1a and then mixed
with FT, there was no detectable caspase activation
(Figure 4). These results indicate that peptoid 1a inhibits
both, endogenous cellular Apaf-1 and rApaf-1.
Initial examination of the ability to inhibit apoptosis in intact
cells, suggested that peptoid 1a suffers of low capacity to
cross cellular membranes. In order to overcome this difficulty,
new series of peptoid 1 analogues were designed covering
three different approaches that could facilitate cellular drug
internalisation (Figure 5a). First, we synthesised a hybrid
peptide/peptoid molecule where peptoid 1 was fused to the
well-characterised cell carrier peptide penetratin, derived from
the sequence of the Drosophila transcription factor antenna-
pedia.32,33 Secondly, we synthesised the analogue cyclo-
peptoid 1, a conformationally constrained peptoid 1 mimetic.
Third, a poly-(L-glutamic acid) (PGA) peptoid 1 conjugate,
PGA-GG-peptoid 1, was also synthesised to explore the
endocytic internalisation approach.34 Penetratin-GG-peptoid
1 and cyclo-peptoid 1 were active as inhibitors in the cell free
assays (data not shown), showed lowered cell toxicity and
allowed their use in cell based assay models. Cell-free
experiments are no suitable as preliminary activity test for
prodrugs, such as the derivative PGA-GG peptoid 1, because
polymer conjugates adopt a unimolecular micelle 3D structure
in solution hiding the active hydrophobic drug at the core.35 To
investigate whether these molecules would inhibit mitochon-
drial mediated apoptosis, assays with: U937 human histiocytic
lymphoma cells challenged with doxorubicin; Saos-2 human
osteosarcoma cells with conditional expression of the
proapoptotic protein Bax (Saos Bax tet-ON) and mouse
embryo fibroblasts (MEFs) challenged with TNF-a were
performed in culture. In the first cell-based model, doxorubicin
induces apoptosis through DNA damage that is transduced
to the mitochondria disturbing the mitochondrial membrane
potential (MMP) and activating executioner caspases through
involvement of the apoptosome. After 12 h, doxorubicin
treated cells demonstrated staining for annexin V-PE (that
specifically binds to exposed phosphatidylserine) and lost
of MMP (Figure 5b and c). When cells were treated with
doxorubicin in the presence of penetratin-GG-peptoid 1 or of
cyclo-peptoid 1, the extent of doxorubicin-induced apoptosis
was remarkably diminished as determined by the lowered
percentage of cells with apoptotic phenotype (Figure 5b and c).
In the Saos-2 cell model, apoptosis is induced by the
conditional expression of Bax through the tet-ON system
(Clontech). Bax is a proapoptotic member of the Bcl-2 family
that induces apoptosis through liberation of cytochrome c
from the mitochondria,36 thus activation of apoptosis solely
relies in the mitochondrial pathway. In this model, PGA-GG-
peptoid 1 showed a dose- and time-dependent prevention of
cell-viability lost induced by expression of Bax as measured in
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) assays (data not shown). In addition and more relevant
for the present study, a time-dependent (up to 72 h) inhibition
of caspase-3 activity was observed (Figure 5d) consistent with
PGA-GG-peptoid 1 inhibition of Apaf-1 dependent apoptosis.
The time dependence of the process is due to the
lysosomotropic intracellular drug delivery mechanism asso-
ciated to PGA-GG-peptoid 1.34 In order to assess specificity
of peptoid 1 for the mitochondrial pathway, apoptosis was
induced by TNFa in MEFs. This is a type I system where
apoptosis is induced by ligation of death receptors of the TNF
family without the involvement of cytochrome c liberation from
the mitochondria. None of the modified forms of peptoid 1
used had any detectable inhibitory effect on TNFa induced
apoptosis (data not shown), indicating that only the mitochon-
drial pathway of caspase activation is inhibited by peptoid 1.
Discussion
Within the last decade enormous progress has been made
in the understanding of the molecular basis of apoptosis
paralleled with an increased interest in the potential clinical
applications of molecules that could modulate the key
events of the apoptotic machinery. Due to the unwanted
activation of the apoptosis program in several diseases, the
initial efforts were directed towards the inhibition of caspases.
Caspase-3 has been one of the more intensely studied
enzymes in terms of potential target in neurodegenerative
diseases and stroke.1,9,37 However, as it is true for other
cellular pathways of relevance in therapy for a potential
therapeutic intervention, more than one isolated protein has
to be targeted to increase the therapeutic value. Accordingly,
the identification of new potential drugs for the treatment of
diseases characterised by excessive apoptosis should be
evaluated and developed. To pursue this goal, we used an
Figure 4 Peptoid 1a inhibits human endogenous Apaf-1 mediated activation of
caspases. A measure of 3 ml aliquots of F1 extract were incubated at 301C by
15 min in the presence or absence of peptoid 1a (50 mM) and then combined with
a 5-ml aliquot of FT extract, 1 mM dATP and further incubated at 371C by 30 min.
DEVDase activity was measured for each of the two samples (F1 and
F1þ peptoid 1a) and for a negative control buffer A
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in vitro reconstituted apoptosome assay suitable to screen
chemical libraries composed either of mixtures or of individual
compounds. A relevant application of this assay is the
identification of a novel class of trialkylglycine-based mole-
cules that inhibit the apoptosome-dependent activation
of caspase-9. Oligomers of N-substituted glycines provide
a class of small, non-natural molecules that are proteolytically
stable and have potent biological activities.38 The newly
identified lead compound peptoid 1a binds reversibly to
Apaf-1 in a cytochrome c noncompetitive manner and
precludes the recruitment and activation of procaspase-9. In
fact, here we show that rApaf-1 in the absence of dATP and
cytochrome c behaves in a size exclusion column as a
140 kDa protein that when incorporated to cellular extracts
containing caspases (FT extract) is able to activate these
enzymes (see Materials and Methods section and Supple-
mentary information). Moreover, we obtain a functional
(B700 kDa) apoptosome when rApaf-1 is subjected to size
Figure 5 Peptoid 1 analogues reduce doxorubicin-induced apoptosis in U937 cells and Bax-induced apoptosis in Saos-2 cells. (a) Structure of penetratin-GG-peptoid
1, cyclo-peptoid 1 and PGA-GG-peptoid 1. The penetratin- and PGA-GG-peptoid 1 were synthesised (see Materials and Methods section) by covalently attaching the
penetratin sequence (one letter code for amino acids) and the poly(L-glutamic acid) (PGA) carrier, respectively, to the peptoid 1 structure flanked by a linker of two glycine
residues. (b) U937 cells were cultured in the absence (white bars) or in the presence of either doxorubicin 0.5 mM (black bars), or doxorubicin 0.5 mM plus penetratin-GG-
peptoid 1, 5 mM (soft grey bars), or doxorubicin 0.5 mM plus cyclo-peptoid 1a, 5 mM (dark grey bars). Apoptosis was evaluated by flow cytometry as the percentage of
cells with exposed phosphatidylserine (annexinV-PE positive) and low DCm (DCm
low). (c) Flow cytometric analysis of PS exposure and DCm of cells treated with the
same procedures as in (b). From the left, control, doxorubicin, doxorubicin plus penetratin-GG-peptoid 1, and doxorubicin plus cyclo-peptoid 1a, respectively. Numbers
refer to the percentages of cells in the different regions. (d) Saos-2 cells were cultured in the absence (control) or in the presence of doxycycline 2mM (Doxy) or
doxycycline 2mM plus PGA-GG-peptoid 1 20 mM (Doxyþ PGA-GG-peptoid 1) at incubation times of 24 h (grey bars), 48 h (white bars) and 72 h (black bars). Caspase 3
activity in Saos-2 cell extracts was measured by the fluorimetric DEVDase assay
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exclusion chromatography in the presence of the FT extract
and the enzymatic activity is inhibited when such a fraction
eluted from the column is treated with peptoid 1a (Figure 3D).
However, when rApaf-1 in the presence of both the FT extract
and peptoid 1a is subjected to size exclusion chromatography,
the protein elutes as a major peak centred at elution volumes
that correspond to a larger complex that could be related
with the previously reported30 B1.4 kDa less active apopto-
some complex (Figure 3D). It is tempting to speculate that
peptoid 1a promotes the oligomerisation event by its binding
to rApaf-1 and induction of an inappropriate for correct
oligomerisation conformation on the protein. If this is true, it
is possible that Apaf-1 could have an allosteric site that could
bind to still undiscovered intrinsic inhibitors that could
participate in the physiological inactivation of the apoptosis
program in certain cells.
Initial structure–activity relationship studies showed that
a peptoid 1a analogue that was synthesised without one of
the dichlorophenethyl moieties lost the ability to inhibit the
apoptosome activity. Noticeably, Nguyen and Wells16 have
reported recently the identification of small molecules bearing
a dichlorobenzylamino moiety as direct activators of apoptosis
and promoters of cytostatic and cytotoxic effects on a variety
of cancer cell lines. Compounds from an indolonone series in
which the amino function was linked to a carbonyl group
displayed the most potent activity. Likewise, a halophenyl
moiety, in this case bearing a trifluoromethyl group, is also
present in the diarylurea derivatives identified recently by
Lademann et al.15 as inhibitors of the formation of the
apoptosome complex. Acylated amino residues located
close to the halophenyl group were also present in these
compounds. Taken together with our results, it appears that a
haloaryl moiety linked directly or through a short alkyl spacer
to an acylated amino group can exert an interaction with the
apoptosome complex. However, those structural complemen-
tary features that confer an activation effect or an inhibitory
activity on the formation of the apoptosome complex and/or
switch on of the apoptosis machinery remain still to be
elucidated.
The parent peptoid 1 exhibit low membrane permeability,
thus exhibiting very modest efficacy arresting apoptosis in
cellular models. To overcome this handicap, we designed
more cell permeable molecules and demonstrated efficacy in
three independent cell models. Treatment of doxorubicin-
challenged U937 cells with selected membrane-permeable
analogues of peptoid 1 decreases phenotypic markers of
apoptosis. When the Apaf-1 inhibitor was supplied through
lysosomotropic delivery, it protected Saos-2 cells from
apoptosis induced by overexpression of the proapoptotic
protein Bax, specific for the mitochondrial pathway. Moreover,
these inhibitors could not prevent cell death activated by TNFa
in a mouse embryonic fibroblast model, indicating that only
apoptosis induced through the mitochondrial pathway can
be blocked by peptoid 1. In summary, although there are
questions that still need to be addressed, a new structural
class of apoptosome inhibitors has been designed based on
oligomers of N-alkylglycines. The discovery of this new class
of inhibitors provides a new medicinal chemistry tool in the
search for lead compounds that could be developed for the
treatment of apoptosis-mediated diseases. Furthermore,
intracellular protein–protein interactions constitute major
control points in many signalling pathways, yet have
frequently proven a difficult target for small molecule
chemistry, often reflecting a protein interface that is extensive,
shallow, and hydrophobic. Such endogenous control points
are typically regulated by other protein domains or their
modifications. Approaches such as the one presented here
reinforce that synthetic molecule provide an alternative




The library and individual N-alkylglycine trimers, pentamers, fluorescent
and cyclic derivatives were synthesised following procedures previously
described.19 For the case of peptoid 1b, introduction of the third
N-alkylglycine residue was carried out by using the pre-formed N-(2,4-
dichlorophenethyl)glycinamide. By this procedure, the formation of cyclic
sideproducts promoted by the presence of a tertiary amino moiety in the
N-alkylglycine present in the second position of the pentamer19 was
circumvented. The hybrid penetratin-GG-peptoid 1 molecule was prepared
by Fmoc-based solid phase synthesis on a 433A Applied Biosystems
Peptide synthesiser where the preassembled peptoidyl 1-resin was
loaded. Peptoids purity was confirmed by HPLC and mass spectrometry.
The HPLC analyses were carried out using a Kromasil 100 C8
(15 0.46 cm, 5 mm) column, with CH3CN/H2O mixtures containing
0.1% TFA at 1 ml/min as mobile phase and monitoring at 220 nm and
showed purities over 80% for all the individual peptoids. High-resolution
mass spectra (HRMS) were carried out at the Mass Spectrometry Service
of the University of Santiago de Compostela (Spain). To synthesise PGA-
GG-peptoid 1 conjugate, poly(L-glutamic acid) sodium salt with a
molecular weight (Mw) of approx. 20 000 Da (Sigma) was used as carrier.
NH2-GG-peptoid 1 was conjugated to the PGA carrier by a carbodiimide-
mediated coupling approach. To stop the reaction, the mixture was poured
into chloroform. The resulting precipitate was collected and dried in
vacuum. The sodium salt of PGA-peptoid conjugate was obtained by
dissolving the product in 1.0 M NaHCO3. The aqueous solution of PGA-
peptoid conjugate was dialysed against distilled water (MW CO 12 000)
and lyophilised to yield the desired conjugated (98% yield) with a 22%
(w/w) peptoid loading as determined by UV.
Production and purification of recombinant
Apaf 1-XL in a baculovirus expression system
Recombinant Apaf-1-XL (rApaf-1) was obtained as described.3 Briefly,
Apaf-1 cDNA (kindly provided by G Nun˜ez, Michigan University) was
subcloned into pFastBac I vector with a C-terminal 9-His-tag. The
expression plasmid was transformed into DH10Bac Escherichia coli cells.
The recombinant bacmids were purified as recommended by the
manufacturer (Invitrogen) and used to transfect SF9 insect cells. The
virus stock was amplified and used to infect suspension cultures. The
infected cells were harvested after 40 h, washed in cold phosphate-
buffered saline (PBS), and resuspended in 5 volumes of buffer A
(20 mM HEPES–KOH pH 8.0, 10 mM KCl, 1.5 mM MgCl2, 1 mM DTT
(dithiothreitol)) supplemented with Complete Protease Inhibitor Cocktail
(Roche). Cells were lysed with a dounce homogeniser and recombinant
protein was purified using a Ni-NTA (Ni2þ -nitrilotriacetate)-agarose
column. The eluted recombinant rApaf-1 protein was concentrated by
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filtration using Microcon YM10 membranes (Millipore), dialysed against
buffer A and stored in multiple aliquots containing 20% glycerol at 801C
after being snap frozen in liquid nitrogen. Before the apoptosome in vitro
reconstitution assays, rApaf-1 was further analysed by size exclusion
chromatography. UV absorption (at 280 nm) showed that protein eluted as
a major single peak with an apparent molecular weight of approximately
150 kDa, consistent with the size of monomeric Apaf-1.39,40 We then
tested whether fractions from size exclusion chromatography activated
caspases by mixing them with FT, a fraction from 293 cell extracts that
lacks Apaf-1 but contains caspase-9, -3 and cytochrome c.14,41 Caspase
activation was triggered by a fraction corresponding to 150 kDa. Finally,
the presence of Apaf-1 in this fraction was confirmed by immunoblot (see
Supplementary information).
In vitro apoptosome assay
Assays were performed incubating 200 ng of purified rApaf-1 with 30 ng
horse heart cytochrome c (Sigma-Aldrich), 3 ml of in vitro translated
[35S]Met procaspase-9 (obtained using the TNT kit from Promega),
0.1 mM dATP, in a total volume of 20 ml of buffer A (20 mM HEPES–KOH,
pH 7.5, 10 mM KCl, 1.5 mM MgCl2, 1 mM NaEDTA, 1 mM NaEGTA,
1 mM DTT, 0.1 mM PMSF). Samples were incubated at 301C for 1 h and
proteins resolved by SDS-PAGE. Gels were dried and caspase-9
processing detected by phosphorimaging in a Fujifilm FLA-3000
Phosphorimager. For the screening of the combinatorial library (see
Supplementary information) and for the final defined peptoids, each
peptoid mixture (at a final concentration of 0.2 mg/ml) or defined peptoid
(at concentrations detailed in the text and figures) were preincubated with
rApaf-1 for 30 min at 301C in a total volume of 16ml before adding
cytochrome c, and in vitro translated [35S]Met procaspase-9 and
assessing caspase-9 processing as described above.
Cell culture and extract preparation
293 cells, a human embryonic kidney cell line, were cultured in Dulbecco’s
modified Eagle’s medium, 10% fetal bovine serum, in 10% CO2. Cells
were seeded in 15 cm plates at 1–2 106 cells per plate and harvested
when confluent (approximately 107 cells per plate). S-100 extracts from
293 cells were prepared from 2 108 cells and fractionated essentially
as described.41 Briefly, fractionation of extracts was carried out by ion-
exchange chromatography using a Mono Q column (Amersham
Pharmacia Biotech). An S-100 extract was separated into three fractions
(F1, F2 and FT) and its composition was confirmed by immunoblot. F1
(5mg of protein/ml) contained Apaf-1 and FT (30 mg of protein/ml)
contained caspases-3 and -9, and cytochrome c. None of these fractions
had caspase activity but a combination of F1 and FT reconstituted
caspase activation. The U937 human histiocytic lymphoma cell line was
obtained from the American Type Culture Collection (Rockville, MD, USA).
The cells were grown in suspension in RPMI 1640 medium (Cellgro;
Fischer Scientific) supplemented with 10% fetal-calf serum (FCS; Omega
Scientific), penicillin (100 mg/ml), streptomycin (100mg/ml), and 2 mM L-
glutamine (Gibco, UK). Cells were maintained at 371C in an atmosphere of
5% carbon dioxide and 95% air and underwent passage twice weekly. The
Saos-2 cell line and MEFs were kindly provided by Karin Vousden (Cancer
Research UK, Glasgow). The cells were grown in Dulbecco’s modified
Eagle’s medium (GIBCO) supplemented with 10% FCS (GIBCO). Cells
were maintained at 371C in an atmosphere of 5% carbon dioxide and
95% air.
Saos-2 extracts were prepared from cells seeded in 3.5 cm plates at
1 105 cells per plate. After different treatments, cells were harvested and
the pellets resuspended in 30ml of extraction buffer (50 mM PIPES,
50 mM KCl, 5 mM EGTA, 2 mM MgCl2, 2 mM DTT supplemented with
protease inhibitor cocktail from Sigma) and kept on ice 5 min. After three
rounds of freeze and thaw, cell lysates were centrifuged at 14 000 r.p.m.
5 min and supernatants were collected. Quantification of total protein
concentration from these cell extracts was performed using the
bicinchoninic acid method (Pierce).
Cell-free caspase activation assays (DEVDase
activity)
rApaf-1 (5–10 ng) was added to FT fraction (5 ml) and incubated with 1 mM
ATP or dATP at 371C, for 30 min. Then, a 3 ml aliquot was mixed with
200ml of caspases assay buffer (PBS, 10% glycerol, 0.1 mM EDTA, 2 mM
DTT) containing 20mM Ac-DEVD-afc (Biomol). Caspase activity was
continuously monitored following the release of fluorescent afc at
301C using a Cytofluor 4000 fluorimeter (lexc¼ 400 nm; lem¼ 508 nm).
DEVDase activity was expressed as either as increase of relative
fluorescence units per min (DFU/min) or as percentage of the initial
fluorescence signal value obtained in the absence of inhibitor when the
inhibitory activity of compounds was evaluated.
MTT cell viability assays
An MTT cell viability assay was used to measure cell recovery of Saos-2
human osteosarcoma cells. Saos-2 cells were seeded in sterile 96-well
microtitre plates at a seeding density of 105 cells/ml and allow settling for
24 h. Doxycycline (2 mg/ml in PBS) was then added and after 30 min
peptoid 1 analogues (0.2 mm filter sterilised) were also added to give a
final concentration of 5–20 mM drug-equiv. After 19 h, 43 and a 67 h
incubation times, MTT (20 ml of a 5 mg/ml solution) was added to each
well, and the cells were further incubated for 5 h. After removal of the
medium, the precipitated formazan crystals were dissolved in optical grade
DMSO (100 ml), and the plates were read at 570 nm using a Wallac 1420
Workstation.
Size exclusion chromatography
rApaf-1 (5mg) was incubated in the absence or in the presence of
cytochrome c (1 mM) at 301C for 15 min with ATP (1 mM) in buffer A,
loaded onto a Superose-6 High Resolution (H-R) column (Amersham
Pharmacia Biotech) and eluted in 50 mM NaCl, HEPES-KOH 20 mM pH
7.0, 0.1% Chaps, 5% sucrose, 5 mM DTT, flow rate 0.5 ml/min. Fractions
(0.5 ml) were collected and to determine which fractions activated
caspases, 4 ml of each fraction was mixed with FT (5 ml) and incubated at
371C for 30 min, after that time caspase activity was assessed as
described above.
Pulldown assays
In total, 250 ng of rApaf-1 were incubated with peptoid 1a or buffer A for
30 min at 301C in a total reaction volume of 20ml. Then 1 mM ATP, 1 mM
cytochrome c and a 5 ml aliquot of an in vitro translated reaction of
noncleavable [35S]Met procaspase-9 (procaspase-9 mutant D315/
330A),26 were added and further incubated for 30 min at 371C. The
reaction was diluted 1 : 10 in cold buffer A and 20 ml of Ni2þ -NTA agarose
beads were used to pull down rApaf-1 complexes for 1 h at 41C. After
three washes with cold buffer A, samples were resolved by SDS-PAGE
and caspase-9 detected by autoradiography.
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Fluorescence polarisation assay
Fluorescence polarisation measurements were made in a Victor2V 1420
Multilabel HTS Counter. A 60 nM solution of 50-60 carboxyfluorescein-
labelled peptoid 1a (named peptoid f1a; lexc¼ 480 nm; lem¼ 535 nm) in
buffer A (total reaction volume was 200ml) was titrated with concentrated
protein solutions. Data were recorded by using a Wallac 1420 Workstation
software. The Kd values were calculated using a two state model.
Evaluation of cell toxicity and flow cytometry
analysis
U937 cells were treated in 24-well plates (1 ml/well) for the times indicated,
with 0.5 mM doxorubicin. In apoptosis inhibition assays, cells were then
treated with 5 mM penetratin-GG-peptoid 1 or cyclo-peptoid 1a. Apoptosis
was analysed by flow cytometry by determining the changes in cell
forward/side scatter and through the simultaneous determination of
phosphatidylserine (PS) exposure and mitochondrial membrane potential
(DCm) loss with annexin V-PE (Caltag) and DiOC6(3) (Molecular Probes),
respectively.42
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